Get the Stockscreener App
6.76
3.21%
0.21
Mimedx Group Inc stock is traded at $6.76, with a volume of 834.51K.
It is up +3.21% in the last 24 hours and up +0.30% over the past month.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
See More
Previous Close:
$6.55
Open:
$6.51
24h Volume:
834.51K
Relative Volume:
1.07
Market Cap:
$1.00B
Revenue:
$342.81M
Net Income/Loss:
$97.67M
P/E Ratio:
11.00
EPS:
0.6145
Net Cash Flow:
$50.46M
1W Performance:
-8.40%
1M Performance:
+0.30%
6M Performance:
-2.03%
1Y Performance:
-26.68%
1-Day Range:
$6.45
$6.7953
1-Week Range:
$6.325
$7.51
52-Week Range:
$5.79
$10.14
Mimedx Group Inc Stock (MDXG) Company Profile
Name
Mimedx Group Inc
Sector
Industry
Phone
(770) 651-9100
Address
1775 W OAK COMMONS COURT, NE, MARIETTA
Compare MDXG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 6.49 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.15 | 3.06B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.51 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.15 | 166.65M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.22 | 492.74M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
0.72 | 0 | 0 | 0 | 0 | 0.00 |
Mimedx Group Inc Stock (MDXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-24 | Initiated | Lake Street | Buy |
| Oct-27-23 | Initiated | Craig Hallum | Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-26-21 | Initiated | Northland Capital | Outperform |
| Mar-19-21 | Initiated | H.C. Wainwright | Buy |
View All
Mimedx Group Inc Stock (MDXG) Latest News
MiMedx Group (MDXG) Is Down 8.4% After Strong CAMPAIGN Trial Results for EPIEFFECT Product – What's Changed - simplywall.st
Is MiMedx Group Inc. stock attractive for long term wealth building - newser.com
Is MiMedx Group Inc. stock a good choice for value investors2025 Retail Activity & Weekly Stock Breakout Alerts - newser.com
Will MiMedx Group Inc. stock maintain dividend yieldFed Meeting & Smart Money Movement Tracker - newser.com
Can MiMedx Group Inc. stock sustain market leadershipJuly 2025 Action & Technical Pattern Based Buy Signals - newser.com
Is MiMedx Group Inc. showing signs of accumulationVolume Spike & Pattern Based Trade Signal System - newser.com
Will MiMedx Group Inc. stock go up soon2025 Historical Comparison & Risk Managed Trade Strategies - newser.com
Will MiMedx Group Inc. stock recover faster than peersJuly 2025 PostEarnings & Free AI Powered Buy and Sell Recommendations - newser.com
How Mimedx Group Inc (MDXG) Affects Rotational Strategy Timing - news.stocktradersdaily.com
MiMedx (MDXG) Just Flashed Golden Cross Signal: Do You Buy? - sharewise.com
Is MiMedx Group Inc. stock attractive for ETFsBond Market & AI Driven Price Forecasts - newser.com
Using data models to predict MiMedx Group Inc. stock movement2025 Big Picture & Technical Buy Zone Confirmations - newser.com
What indicators show strength in MiMedx Group Inc.July 2025 PostEarnings & Daily Price Action Insights - newser.com
Is MiMedx Group Inc. stock a safe investment in uncertain marketsJuly 2025 Opening Moves & Scalable Portfolio Growth Ideas - newser.com
Is MiMedx Group Inc. stock attractive for retirement portfoliosRate Cut & Weekly Consistent Profit Watchlists - Fundação Cultural do Pará
MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial - The Manila Times
MiMedx Reports Positive Interim Results for EPIEFFECT in CAMPAIGN Trial, Highlighting Clinical Superiority Over Standard of Care - Quiver Quantitative
MiMedx (Nasdaq: MDXG) RCT in diabetic foot ulcers shows 98.5% superiority vs SOC - Stock Titan
Chief Commercial Officer Of MiMedx Group Sold 71% Of Their Shares - simplywall.st
MIMEDX to Participate in Upcoming Investor Conferences - The Manila Times
Mimedx Group Inc Stock (MDXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):